Volume Alert - TEVA 57.30 Teva Pharmaceutical Industries Ltd $TEVA Hit a high today of 58.61 Closing the day 10:30 at 57.30 +0.06 +0.10% With a day low of 56.99 and a total volume of 2,803,780.
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Why Mylan Will Continue To Soar
Main Street Wins - at Seeking Alpha - 2 hrs 11 mins ago
MYL: 55.98 (+0.85), TEVA: 57.31 (+0.07)
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 33 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 262.38 (+14.44), PFE: 30.68 (+0.36), TEVA: 57.31 (+0.07)
/R E P E A T -- Teva Canada Announces the Launch of (Pr)Teva-Celecoxib, a generic of (Pr)Celebrex®/
CNW Group - Tue Nov 18, 8:00AM CST
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of (Pr)Celebrex(®) for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. (Pr)Teva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
TEVA: 57.31 (+0.07)
Teva Launches Liquid Formulation of TREANDA(R) (bendamustine HCI) Injection in U.S.
Business Wire - Tue Nov 18, 7:02AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the commercial availability of a liquid formulation of TREANDA(R) (bendamustine HCI) Injection. This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the required dose of medicine to the infusion bag and administering to a patient. By eliminating the need for reconstitution, preparation time for healthcare professionals is reduced.
TEVA: 57.31 (+0.07)
Teva, Fedex Shares Look Fantastic, Arch Coal Headed Lower
at The Street - Mon Nov 17, 4:36PM CST
Shares of Teva remain relatively inexpensive despite the stock's sharp move higher this year, said Andrew Ver Planck, portfolio manager for the MainStay International Opportunities Fund.
FDX: 172.41 (+1.09), ACI: 2.55 (-0.10), TEVA: 57.31 (+0.07)
Teva Canada Announces the Launch of (Pr)Teva-Celecoxib, a generic of (Pr)Celebrex®
CNW Group - Mon Nov 17, 4:16PM CST
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of (Pr)Celebrex(®) for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. (Pr)Teva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
TEVA: 57.31 (+0.07)
Teva Pharmaceutical Industries Earnings Review: 18 Days after Announcement Shares Up 1.1% (TEVA)
Comtex SmarTrend(R) - Mon Nov 17, 2:41PM CST
18 days ago, on October 30th, 2014, Teva Pharmaceutical Industries (NASDAQ:TEVA) reported its earnings. Analysts, on average, expected earnings of $1.24 per share on sales of $5.1 billion. Teva Pharmaceutical Industries actually reported a break-even quarter on sales of $5.1 billion, missing EPS estimates by $1.24 and missing revenue estimates by $37.1 million. Since the company's report, shares of Teva Pharmaceutical Industries have risen from $56.47 to $57.07, representing a gain of 1.1% in the past 18 days.
TEVA: 57.31 (+0.07)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 2.17% Sell Off
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.31 (+0.07)
Teva Pharmaceutical Industries Falls 2.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.31 (+0.07)
TEVA: Copaxone Patent Expiry Worries Are Overblown
Alpha Gen Capital - at Seeking Alpha - Tue Nov 11, 2:52PM CST
TEVA: 57.31 (+0.07)
Insys Q3 Beats Estimates, Helping Stock Rebound
at Investor's Business Daily - Tue Nov 11, 10:33AM CST
Specialty drugmaker Insys Therapeutics (INSY) beat Wall Street's Q3 estimates Tuesday, sending the stock up around 6% in early trading on the stock market today. Insys' revenue in the quarter totaled $58.3 million, double the year-earlier quarter and...
INSY: 38.60 (+0.71), GWPH: 79.24 (+2.68), TEVA: 57.31 (+0.07), GSK: 46.21 (+0.33)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 110.30 (-1.32), GILD: 102.02 (+1.58), MRK: 60.07 (+0.61), DNDN: 0.17 (+0.02), AZN: 73.67 (+1.17), TEVA: 57.31 (+0.07), ABBV: 65.95 (+0.91), GSK: 46.21 (+0.33), BMY: 58.67 (+0.24), NVS: 95.66 (+1.28)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 60.07 (+0.61), AZN: 73.67 (+1.17), AMGN: 160.99 (+1.85), TEVA: 57.31 (+0.07), THRX: 13.42 (+0.12), GSK: 46.21 (+0.33), SNY: 48.30 (+0.76), REGN: 410.01 (+10.36), NVS: 95.66 (+1.28)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 10.00 (+0.17), TEVA: 57.31 (+0.07), ASPX: 25.26 (+0.42), GSK: 46.21 (+0.33), PRAN: 1.66 (-0.02), VRX.TO: 159.90 (+5.50)
Teva Pharmaceutical Industries Earnings Review: 11 Days after Announcement Shares Up 2.2% (TEVA)
Comtex SmarTrend(R) - Mon Nov 10, 11:40AM CST
11 days ago, on October 30th, 2014, Teva Pharmaceutical Industries (NASDAQ:TEVA) reported its earnings. Analysts, on average, expected earnings of $1.24 per share on sales of $5.1 billion. The company actually reported a break-even quarter on sales of $5.1 billion, missing EPS estimates by $1.24 and missing revenue estimates by $37.1 million. Shares of Teva Pharmaceutical Industries have climbed from $56.47 to $57.70, representing a gain of 2.2% since the company reported earnings 11 days ago.
TEVA: 57.31 (+0.07)
Dividend Contenders, Future Champions Or Future Failures: Part 6
Stan Stafford - at Seeking Alpha - Fri Nov 07, 5:13PM CST
PRGO: 157.45 (+4.14), NVO: 44.16 (+0.56), CAH: 80.86 (+0.50), TEVA: 57.31 (+0.07)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 305.25 (+2.83), ALNY: 90.62 (+1.64), ISIS: 49.81 (+0.80), OGXI: 2.16 (-0.04), TEVA: 57.31 (+0.07), RGLS: 18.33 (+1.48), GSK: 46.21 (+0.33), SNY: 48.30 (+0.76)
Uptrend Call Working As Teva Pharmaceutical Industries Stock Rises 10.2% (TEVA)
Comtex SmarTrend(R) - Fri Nov 07, 10:06AM CST
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on October 21st, 2014 at $52.51. In approximately 2 weeks, Teva Pharmaceutical Industries has returned 10.17% as of today's recent price of $57.85.
TEVA: 57.31 (+0.07)
Champions Oncology: Marking A Shift Toward Drug Discovery
Ian C. Clift - at Seeking Alpha - Fri Nov 07, 9:14AM CST
Big Pharma is big business, but at a high cost. The most comprehensive industry estimate of productivity for investigational drugs to FDA approval is between 10 to 15% from time of initial clinical investigation. This is due primarily to several...
TEVA: 57.31 (+0.07)
Teva Presents Positive Safety and Efficacy Data for QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL(R) (beclomethasone dipropionate) Nasal Aerosol 80 g/day in children 4-11 years of age with perennial - or "year round" - allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis (SAR) in patients 12 years of age and older. The data will be presented at the 2014 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Atlanta, Georgia on Saturday, November 8 and Sunday, November 9.
TEVA: 57.31 (+0.07)
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Why Mylan Will Continue To Soar
Main Street Wins - at Seeking Alpha - 2 hrs 11 mins ago
MYL: 55.98 (+0.85), TEVA: 57.31 (+0.07)
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 33 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 262.38 (+14.44), PFE: 30.68 (+0.36), TEVA: 57.31 (+0.07)
/R E P E A T -- Teva Canada Announces the Launch of (Pr)Teva-Celecoxib, a generic of (Pr)Celebrex®/
CNW Group - Tue Nov 18, 8:00AM CST
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of (Pr)Celebrex(®) for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. (Pr)Teva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
TEVA: 57.31 (+0.07)
Teva Launches Liquid Formulation of TREANDA(R) (bendamustine HCI) Injection in U.S.
Business Wire - Tue Nov 18, 7:02AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the commercial availability of a liquid formulation of TREANDA(R) (bendamustine HCI) Injection. This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the required dose of medicine to the infusion bag and administering to a patient. By eliminating the need for reconstitution, preparation time for healthcare professionals is reduced.
TEVA: 57.31 (+0.07)
Teva, Fedex Shares Look Fantastic, Arch Coal Headed Lower
at The Street - Mon Nov 17, 4:36PM CST
Shares of Teva remain relatively inexpensive despite the stock's sharp move higher this year, said Andrew Ver Planck, portfolio manager for the MainStay International Opportunities Fund.
FDX: 172.41 (+1.09), ACI: 2.55 (-0.10), TEVA: 57.31 (+0.07)
Teva Canada Announces the Launch of (Pr)Teva-Celecoxib, a generic of (Pr)Celebrex®
CNW Group - Mon Nov 17, 4:16PM CST
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of (Pr)Celebrex(®) for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. (Pr)Teva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
TEVA: 57.31 (+0.07)
Teva Pharmaceutical Industries Earnings Review: 18 Days after Announcement Shares Up 1.1% (TEVA)
Comtex SmarTrend(R) - Mon Nov 17, 2:41PM CST
18 days ago, on October 30th, 2014, Teva Pharmaceutical Industries (NASDAQ:TEVA) reported its earnings. Analysts, on average, expected earnings of $1.24 per share on sales of $5.1 billion. Teva Pharmaceutical Industries actually reported a break-even quarter on sales of $5.1 billion, missing EPS estimates by $1.24 and missing revenue estimates by $37.1 million. Since the company's report, shares of Teva Pharmaceutical Industries have risen from $56.47 to $57.07, representing a gain of 1.1% in the past 18 days.
TEVA: 57.31 (+0.07)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 2.17% Sell Off
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.31 (+0.07)
Teva Pharmaceutical Industries Falls 2.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.31 (+0.07)
TEVA: Copaxone Patent Expiry Worries Are Overblown
Alpha Gen Capital - at Seeking Alpha - Tue Nov 11, 2:52PM CST
TEVA: 57.31 (+0.07)
Insys Q3 Beats Estimates, Helping Stock Rebound
at Investor's Business Daily - Tue Nov 11, 10:33AM CST
Specialty drugmaker Insys Therapeutics (INSY) beat Wall Street's Q3 estimates Tuesday, sending the stock up around 6% in early trading on the stock market today. Insys' revenue in the quarter totaled $58.3 million, double the year-earlier quarter and...
INSY: 38.60 (+0.71), GWPH: 79.24 (+2.68), TEVA: 57.31 (+0.07), GSK: 46.21 (+0.33)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 110.30 (-1.32), GILD: 102.02 (+1.58), MRK: 60.07 (+0.61), DNDN: 0.17 (+0.02), AZN: 73.67 (+1.17), TEVA: 57.31 (+0.07), ABBV: 65.95 (+0.91), GSK: 46.21 (+0.33), BMY: 58.67 (+0.24), NVS: 95.66 (+1.28)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 60.07 (+0.61), AZN: 73.67 (+1.17), AMGN: 160.99 (+1.85), TEVA: 57.31 (+0.07), THRX: 13.42 (+0.12), GSK: 46.21 (+0.33), SNY: 48.30 (+0.76), REGN: 410.01 (+10.36), NVS: 95.66 (+1.28)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 10.00 (+0.17), TEVA: 57.31 (+0.07), ASPX: 25.26 (+0.42), GSK: 46.21 (+0.33), PRAN: 1.66 (-0.02), VRX.TO: 159.90 (+5.50)
Teva Pharmaceutical Industries Earnings Review: 11 Days after Announcement Shares Up 2.2% (TEVA)
Comtex SmarTrend(R) - Mon Nov 10, 11:40AM CST
11 days ago, on October 30th, 2014, Teva Pharmaceutical Industries (NASDAQ:TEVA) reported its earnings. Analysts, on average, expected earnings of $1.24 per share on sales of $5.1 billion. The company actually reported a break-even quarter on sales of $5.1 billion, missing EPS estimates by $1.24 and missing revenue estimates by $37.1 million. Shares of Teva Pharmaceutical Industries have climbed from $56.47 to $57.70, representing a gain of 2.2% since the company reported earnings 11 days ago.
TEVA: 57.31 (+0.07)
Dividend Contenders, Future Champions Or Future Failures: Part 6
Stan Stafford - at Seeking Alpha - Fri Nov 07, 5:13PM CST
PRGO: 157.45 (+4.14), NVO: 44.16 (+0.56), CAH: 80.86 (+0.50), TEVA: 57.31 (+0.07)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 305.25 (+2.83), ALNY: 90.62 (+1.64), ISIS: 49.81 (+0.80), OGXI: 2.16 (-0.04), TEVA: 57.31 (+0.07), RGLS: 18.33 (+1.48), GSK: 46.21 (+0.33), SNY: 48.30 (+0.76)
Uptrend Call Working As Teva Pharmaceutical Industries Stock Rises 10.2% (TEVA)
Comtex SmarTrend(R) - Fri Nov 07, 10:06AM CST
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on October 21st, 2014 at $52.51. In approximately 2 weeks, Teva Pharmaceutical Industries has returned 10.17% as of today's recent price of $57.85.
TEVA: 57.31 (+0.07)
Champions Oncology: Marking A Shift Toward Drug Discovery
Ian C. Clift - at Seeking Alpha - Fri Nov 07, 9:14AM CST
Big Pharma is big business, but at a high cost. The most comprehensive industry estimate of productivity for investigational drugs to FDA approval is between 10 to 15% from time of initial clinical investigation. This is due primarily to several...
TEVA: 57.31 (+0.07)
Teva Presents Positive Safety and Efficacy Data for QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL(R) (beclomethasone dipropionate) Nasal Aerosol 80 g/day in children 4-11 years of age with perennial - or "year round" - allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis (SAR) in patients 12 years of age and older. The data will be presented at the 2014 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Atlanta, Georgia on Saturday, November 8 and Sunday, November 9.
TEVA: 57.31 (+0.07)
